Role of aromatase inhibitors in breast cancer

Area of Science:

• Endocrinology
• Oncology
• Pharmacology

Background:

• Aromatase inhibitors (AIs) are crucial in managing hormone-sensitive breast cancer.
• Their mechanism involves suppressing endogenous estrogens, distinct from tamoxifen's receptor interaction.
• AIs are investigated in both postmenopausal and premenopausal women undergoing ovarian suppression.

Purpose of the Study:

• To provide an overview of the current and future applications of aromatase inhibitors in breast cancer treatment.
• To compare the efficacy, safety, and tolerability profiles of different classes of aromatase inhibitors.
• To explore the potential for sequential use of aromatase inhibitors due to lack of cross-resistance.

Main Methods:

• Review of existing literature on aromatase inhibitors in breast cancer.
• Comparison of steroidal and nonsteroidal aromatase inhibitors.
• Analysis of clinical and animal studies on exemestane's effects on bone and lipid metabolism.

Main Results:

• Aromatase inhibitors demonstrate high efficacy in suppressing estrogen levels.
• They exhibit favorable safety and tolerability profiles, challenging tamoxifen as a first-line treatment.
• Steroidal AIs, like exemestane, show potential for better end-organ effects, particularly on bone and lipid metabolism.

Conclusions:

• Aromatase inhibitors represent a significant advancement in endocrine therapy for breast cancer.
• Sequential use of different AI classes may prolong treatment duration.
• Steroidal aromatase inhibitors may offer advantages in long-term management due to favorable side-effect profiles.